Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from BioPharmaDive

00:27 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "BioPharmaDive" found in our extensive news archives from over 250 global news sources.

More Information about BioPharmaDive on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioPharmaDive for you to read. Along with our medical data and news we also list BioPharmaDive Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharmaDive Companies for you to search.

Showing News Articles 1–25 of 1,000+ from BioPharmaDive

Saturday 16th February 2019

Hunt for immunotherapy combinations turns up success in kidney cancer

Drug pairings tested by Merck & Co. and Pfizer proved effective, and could soon compete with Bristol-Myers' combo in metastatic renal cell carcinoma. 

Friday 15th February 2019

As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi

With the targeted cancer drug now exclusively held by Bayer, Lilly's buyout of Loxo becomes an $8 billion bet on the promise of the biotech's RET inhibitor.

CMS unveils CAR-T proposal, with emphasis on patient outcomes

High price tags and a potential one-time administration have challenged CMS to figure out reimbursement for CAR-T cell therapies.

New prostate cancer data puts Bayer drug in line with Pfizer, J&J rivals

Pfizer and J&J are already on the market with products for non-metastatic prostate cancer. Bayer aims to compete with its drug darolutamide.

Thursday 14th February 2019

Teva set to shed 11 manufacturing sites in 2019

The drugmaker's plans are part of a broad cost-cutting drive aimed at shrinking its spending base amid ongoing challenges in its generics business.

DBV sets sights on FDA resubmission for peanut allergy treatment

A refile for Viaskin Peanut boosted the company's shares, but rival Aimmune still looks in position to be first to market.

Novartis secures regulatory 'fast pass' in US OK for tropical disease drug

With the FDA's nod, Egaten is now the first approved therapy in the U.S. for an infectious disease caused by parasites found in contaminated food and water.

AstraZeneca retires Medimmune name amid sales turnaround

Erasing the storied biotech brand is part of a major restructuring designed to support AstraZeneca's return to growth and boost R&D productivity. 

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Announcement of the trials comes as the drugmaker unveiled mid-stage data from testing of several Keytruda combos in the common cancer type.

Charles River Labs snaps up early-stage CRO for $510M

Acquiring Citoxlab will build out the contract research organization's footprint into Eastern Europe.

Wednesday 13th February 2019

Jazz set to lose rights to Erwinaze after partner cancels deal

While the lost rights would be a hit to Jazz's revenues, the company has a recombinant version of drug that analysts believe could cushion the blow. 

Ironwood to cut 35 more jobs as company split nears

The new cuts bring Ironwood's workforce reduction total to about 235 employees over the past year.

Teva predicts bleak year ahead as generic, Copaxone sales drop

A turnaround for Teva has proved elusive, with competitive pressures overshadowing the Israeli drugmaker's deepening push into specialty medicine.

Mylan launches Advair generic at 70% discount

While a long time coming, Mylan's copycat version now looks set to take a bite out of GSK's respiratory drug sales.

Tuesday 12th February 2019

J&J's esketamine wins backing of key advisory panel

Committee experts recommended the FDA approve the depression drug, giving cover for the agency to take a more "flexible" approach in its review.

Merck kidney cancer data impresses, putting pressure on Bristol-Myers

Trial results showing a strong survival benefit for Merck's Keytruda in renal cancer could help the pharma make further gains on its immuno-oncology rival.

Gilead's lead NASH drug not so STELLAR in first late-stage readout

While predicted by many, selonsertib's failure in STELLAR 4 further dims the drug's prospects as a treatment for the fatty liver disease.

Celgene's Revlimid defenses withstand another challenge

A U.S. patent board declined to institute inter partes review of key patents held by Celgene on its multiple myeloma drug.

Xtandi results bolster Pfizer, Astellas in prostate cancer

Strong data in hormone-sensitive prostate cancer could help Pfizer and Astellas as they face a challenger in J&J's Erleada.

Monday 11th February 2019

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

The drugmakers will make Praluent available for 60% less than the cholesterol drug's original price, a decision reflective of persistent commercial hurdles.

Eylea's PANORAMA data give fuller view of efficacy in label expansion bid

Regeneron's blockbuster eye drug benefited certain patients with severe diabetic retinopathy, a market the big biotech is eager to break into.

UniQure update bolsters outlook for hemophilia B gene therapy

While data came from only three patients, treatment with uniQure's experimental gene therapy led to Factor IX activity levels high enough to reduce bleeding risk.

Friday 8th February 2019

Seres cuts 30% of workforce in pipeline shift

Long a pioneer in studying microbiome therapies, Seres has run into hurdles that've spurred it to focus resources on a few priority late-stage assets.

Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection

The agency will re-inspect a New Jersey manufacturing facility as part of a regulatory resubmission for the company's lead drug candidate.

Approving J&J's new depression drug would be an unusual move for the FDA

Esketamine's clinical track record could raise questions about its efficacy, which will be a key topic during a joint advisory committee meeting next week.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks